This study aims to provide a comprehensive review of the currently available evidence regarding the use of bevacizumab in pediatric patients with NF2-related schwannomatosis, with a focus on its effects on hearing, tumor progression, and treatment-related toxicity. Here, NF2 is linked to neoplasm.